Company Monitoring Page for Janssen

latest headlines for company on cafepharma

AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis
Endpoints
Tue, 11/2/21 - 10:48 am
Tags:
atopic dermatitis, eczema, nocturnal scratch, digital endpoint, AbbVie, Janssen, JNJ, Novartis, Pfizer, UCB Pharma, digital pharma
Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab
BioSpace
Thu, 10/21/21 - 09:24 am
Tags:
F-star Therapeutics, Janssen, FS120, ESMO, clinical trials
Janssen, Brickell and ViiV are Knocking on FDA's Door
BioSpace
Sat, 10/9/21 - 10:56 pm
Tags:
FDA, Janssen, Stelara, juvenile psoriatic arthritis, Brickell Bio, sofpironium bromide gel, ViiV Healthcare, HIV, Triumeq
FDA Approvals Roundup: Kerendia, Padcev, Darzalex Faspro
RAPS.org
Thu, 07/15/21 - 12:34 pm
Tags:
FDA, drug approvals, Bayer, Kerendia, Astellas, Padcev, Teva Pharmaceutical, ArmonAir RespiClick, Janssen, Darzalex Faspro
Legend Biotech and Janssen establish Belgium cell therapy site
Biopharma Reporter
Mon, 06/28/21 - 10:47 am
Tags:
Legend Biotech, Janssen, Belgium, cell therapy
Johnson & Johnson single-shot Covid vaccine approved for use in UK
The Guardian, UK
Fri, 05/28/21 - 11:17 am
Tags:
JNJ, COVID-19, vaccines, UK, Janssen
Straight after its first cancer bispecific OK, J&J highlights two more at ASCO
Pharmaforum
Tue, 05/25/21 - 10:59 am
Tags:
JNJ, ASCO 2021, talquetamab, teclistamab, Genmab, Janssen, Multiple Myeloma
Guardant’s Partnership with Janssen Bears Fruit
Medical Devices and Diagnostics Industry
Mon, 05/24/21 - 11:25 pm
Tags:
Guardant Health, Janssen, liquid biopsies, FDA, Guardant 360 CDx, Rybrevant, non-small cell lung cancer, diagnostics
J&J beats Tagrisso and Takeda to the punch in key NSCLC subset, picking up new FDA approval
Endpoints
Sun, 05/23/21 - 03:08 pm
Tags:
JNJ, non-small cell lung cancer, Janssen, amivantamab, FDA
FDA approves Janssen’s PONVORY for treatment of multiple sclerosis
Pharmaceutical Business Review
Mon, 03/22/21 - 10:35 am
Tags:
JNJ, Janssen, FDA, Ponvory, relapsing multiple sclerosis, MS
Janssen's Psoriatic Arthritis Drug Proves Long-Term Efficacy in Two-Year Trial
BioSpace
Tue, 03/16/21 - 10:40 pm
Tags:
JNJ, Janssen, clinical trials, Tremfya, psoriatic arthritis
FDA scientists endorse J&J’s Covid vaccine, as new data shed light on efficacy
Stat
Wed, 02/24/21 - 11:30 am
Tags:
JNJ, Janssen, FDA, vaccines, COVID-19
As J&J eyes approval for its one-shot COVID-19 vax, it sends off phase 3 data for a swift WHO listing
Fierce Biotech
Sun, 02/21/21 - 11:58 pm
Tags:
JNJ, WHO, Janssen, COVID-19, vaccines
Janssen's COVID vaccine application submitted to EMA
RAPS.org
Tue, 02/16/21 - 11:38 pm
Tags:
JNJ, Janssen, EMA, Europe, vaccines, COVID-19
1 Green Flag and 1 Red Flag for Johnson & Johnson's Vaccine Candidate
Motley Fool
Sat, 02/13/21 - 11:07 pm
Tags:
JNJ, Janssen, vaccines, COVID-19
Janssen Shows 35% Drop in Mortality with Prostate Cancer Drug
BioSpace
Wed, 02/10/21 - 12:01 am
Tags:
Janssen, JNJ, Erleada, prostate cancer, clinical trials
Janssen flags accelerated approval milestone in Europe for CAR-T therapy
Biopharma Reporter
Mon, 02/1/21 - 11:04 pm
Tags:
JNJ, Janssen, CAR-T, EMA, Europe, cilta-cel
Verana strikes research collaboration with Janssen on ophthalmology and urology
MedCity News
Wed, 01/27/21 - 08:02 pm
Tags:
Verana Health, JNJ, Janssen, data analytics, diabetic retinopathy, diabetic macular edema
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA
Pharmaforum
Tue, 12/22/20 - 10:41 am
Tags:
JNJ, Janssen, Multiple Myeloma, CAR-T, cilta-cel, FDA, Bristol-Myers Squibb, ide-cel
J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront
Endpoints
Mon, 12/7/20 - 10:45 am
Tags:
JNJ, Xencor, Janssen, bispecific antibodies, prostate cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.